Identifying the most relevant assay for your therapeutic area and disease indication is key to a successful screening campaign. Developing the right screening cascade that is designed to increase the chances of success can save months of time and eliminate wasted resources. Leveraging the scientific expertise built from developing over 7,500 biochemical and cell-based assays that accurately reflect compound pharmacology, our scientists can help design the most effective screening strategy for your individual program needs and screen a library of 50,000-100,000 compounds a week while adjusting to any changing program needs.
High-Throughput Screening Capabilities
- Save months of assay development time – A comprehensive portfolio of over 7,500 biochemical and cell-based assays that are available off-the-shelf for primary screening, hit confirmation, selectivity, and orthogonal testing
- Technology that fits your program goals – Assay readouts from a wide range of technologies including luminescence, radiolabeled assays, qPCR, TR-FRET, and mass spectrometry assays.
- Screen up to 50,000 compounds per week – State of the art equipment with ECHO Acoustics platform for compound dispensing, reformatting and automated robotic systems for screening.
- Access to broad screening collections – Diversity library, GPCR, Kinase, PPI, and ion channel-focused libraries for immediate incorporation into an HTS campaign with the ability to use client-supplied libraries.
- Reduce downstream attrition rates – Unique assays available for orthogonal testing and selectivity testing, ADME testing, and safety pharmacology testing.
- Expand your expertise – Capabilities to support any custom cell line and assay development using established technologies like TR-FRET, Reporter based Assays, and FP assays.
Speak with an expert to initiate an HTS campaign.
